Sam Tomlinson appointed as
VP of Global Drug Safety.
Sam has over 20 years strategic and operational experience and will develop and direct our clinical and non-clinical pharmacovigilance services and solutions.
We are happy to announce that Sam Tomlinson has joined Arriello to develop and direct our clinical and non-clinical pharmacovigilance services and solutions, and lead our expanding multi-national PV team.
She has over 20 years strategic and operational experience in global Pharmacovigilance in both large pharma and small to medium sized pharma organizations.
Sam started her Pharmacovigilance career working at Eli Lilly and has gone on to lead global pharmacovigilance teams working across a broad range of therapeutic areas, most recently working with specialty pharma building safety and risk management systems.
Sam also has experience as an EU QPPV and her expertise spans across the product lifecycle from clinical trials, through post marketing and product discontinuation.
Additionally, she has managed and supported numerous Health Authority inspections including EMA, FDA, MHRA, ANSM, Health Canada, HPRA, and AIFA.
Sam will report to Arriello’s COO Anna Lukyanova.
Latest News
View all
